Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.

PLoS One 2016 22;11(4):e0154133. Epub 2016 Apr 22.

Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.

We evaluated the preliminary efficacy and feasibility of a next-generation sequencing (NGS)-based targeted anticancer therapy in refractory solid tumors at a Korean institution. Thirty-six patients with advanced cancer underwent molecular profiling with NGS with the intent of clinical application of available matched targeted agents. Formalin-fixed paraffin-embedded (FFPE) tumors were sequenced using the Comprehensive Cancer Panel (CCP) or FoundationOne in the Clinical Laboratory Improvement Amendments-certified laboratory in the USA. Response evaluations were performed according to RECIST v1.1. Four specimens did not pass the DNA quality test and 32 specimens were successfully sequenced with CCP (n = 31) and FoundationOne (n = 1). Of the 32 sequenced patients, 10 (31.3%) were ≤40 years. Twelve patients (37.5%) had received ≥3 types of prior systemic therapies. Of 24 patients with actionable mutations, five were given genotype-matched drugs corresponding to actionable mutations: everolimus to PIK3CA mutation in parotid carcinosarcoma (partial response) and tracheal squamous cell carcinoma (stable disease; 21% reduction), sorafenib to PDGFRA mutation in auditory canal adenocarcinoma (partial response), sorafenib to BRAF mutation in microcytic adnexal carcinoma (progressive disease), and afatinib to ERBB2 mutation in esophageal adenocarcinoma (progressive disease). Nineteen of 24 patients with actionable mutations could not undergo targeted therapy based on genomic testing because of declining performance status (10/24, 41.7%), stable disease with previous treatment (5/24, 20.8%), and lack of access to targeted medication (4/24, 16.7%). NGS-based targeted therapy may be a good option in selected patients with refractory solid tumors. To pursue this strategy in Korea, lack of access to clinical-grade NGS assays and a limited number of genotype-matched targeted medications needs to be addressed and resolved.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154133PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841558PMC
March 2017
16 Reads

Publication Analysis

Top Keywords

refractory solid
12
solid tumors
12
actionable mutations
12
tumors korean
8
ccp foundationone
8
targeted therapy
8
korean institution
8
partial response
8
progressive disease
8
therapy refractory
8
ngs-based targeted
8
lack access
8
patients actionable
8
stable disease
8
targeted anticancer
8
anticancer therapy
8
targeted
7
patients
6
313% ≤40
4
disease nineteen
4

References

(Supplied by CrossRef)
Cancer statistics, 2015
RL Siegel et al.
CA Cancer J Clin 2015
Economic Burden of Cancer in Korea during 2000–2010
KS Lee et al.
Cancer Res Treat 2015

Similar Publications